Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • Northwest Biotherapeutics' Accumulated Depreciation & Amortization changed 0.0% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.6 million for FY2024, which is 4400.93% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Accumulated Depreciation & Amortization of $1.3 million as of Q3 2025, which was down 0.0% from $900000.0 recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Accumulated Depreciation & Amortization peaked at $5.6 million during Q4 2024, and registered a low of $400000.0 during Q1 2024.
  • In the last 5 years, Northwest Biotherapeutics' Accumulated Depreciation & Amortization had a median value of $1.3 million in 2024 and averaged $1.9 million.
  • In the last 5 years, Northwest Biotherapeutics' Accumulated Depreciation & Amortization soared by 10959.41% in 2022 and then crashed by 8476.77% in 2024.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Accumulated Depreciation & Amortization stood at $1.1 million in 2021, then soared by 109.59% to $2.3 million in 2022, then surged by 69.72% to $3.9 million in 2023, then skyrocketed by 44.01% to $5.6 million in 2024, then tumbled by 76.59% to $1.3 million in 2025.
  • Its Accumulated Depreciation & Amortization was $1.3 million in Q3 2025, compared to $900000.0 in Q2 2025 and $400000.0 in Q1 2025.